Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune disease
Boehringer Ingelheim was an early adopter of Medidata's electronic data collection (EDC) platform for clinical trials, and has now extended and expanded the contract.